MAGE-10 (290-298)

MAGE-10 (290-298) is a synthetic peptide fragment derived from the melanoma-associated antigen 10 (MAGE-10), specifically corresponding to amino acid residues 290 through 298 of the parent protein. As a member of the MAGE family, this peptide is of significant interest in immunological and cancer research due to its role as a defined epitope recognized by the immune system. The sequence's biochemical relevance is closely tied to its function as a minimal antigenic determinant, making it a valuable tool for studies focused on antigen presentation, T-cell recognition, and the broader mechanisms of tumor immunology. Its defined structure and sequence specificity allow for precise experimental manipulation, supporting a range of applications in both basic and translational research settings.

Epitope Mapping: MAGE-10 (290-298) is widely used in epitope mapping experiments aimed at elucidating the precise regions of the MAGE-10 protein recognized by cytotoxic T lymphocytes. By incorporating this peptide into assays such as enzyme-linked immunospot (ELISPOT) or peptide-MHC tetramer staining, researchers can identify and characterize T-cell populations that specifically recognize this antigenic sequence. Such studies are essential for advancing the understanding of immune surveillance in the context of tumor-associated antigens and for dissecting the molecular interactions underlying antigen-specific immune responses.

Immunogenicity Assessment: The peptide serves as a standard reagent for evaluating the immunogenic properties of MAGE-10-derived epitopes in vitro. By stimulating peripheral blood mononuclear cells or isolated T-cell clones with the sequence, investigators can assess functional parameters such as cytokine production, proliferation, and cytotoxic activity. These experiments are instrumental in determining the immunostimulatory potential of the epitope and in optimizing protocols for generating antigen-specific immune responses in experimental models.

T-Cell Receptor Specificity Studies: Utilizing the MAGE-10 (290-298) peptide enables detailed analysis of T-cell receptor (TCR) specificity and affinity. By presenting the peptide in the context of major histocompatibility complex (MHC) molecules on antigen-presenting cells, researchers can probe the fine specificity of TCR-peptide-MHC interactions. Such studies contribute to the selection and engineering of high-affinity TCRs for adoptive cell transfer experiments and provide mechanistic insights into T-cell recognition of tumor antigens.

Peptide-MHC Binding Assays: The defined sequence of this peptide supports its use in quantitative binding assays to evaluate its affinity for various MHC class I molecules. By measuring the stability and binding kinetics of peptide-MHC complexes, researchers can assess the suitability of this epitope for use in immunological assays and vaccine development studies. These data are critical for understanding the molecular determinants of antigen presentation and for selecting optimal peptide candidates for further investigation.

Peptide-Based Vaccine Research: MAGE-10 (290-298) is frequently incorporated into preclinical studies aimed at developing peptide-based vaccines targeting tumor antigens. Its well-characterized immunogenicity and defined sequence make it an ideal candidate for formulating experimental vaccine constructs designed to elicit robust cellular immune responses. By serving as a model antigen, the peptide allows for the systematic evaluation of adjuvants, delivery systems, and immunization protocols, thereby facilitating the rational design of next-generation cancer immunotherapies.

Collectively, these applications underscore the utility of MAGE-10 (290-298) as a versatile and scientifically robust tool in immunological and cancer research. Its role in enabling precise experimental approaches to antigen recognition, T-cell specificity, and immune activation highlights its value to investigators seeking to unravel the complexities of tumor immunology and to advance the field of peptide-based immunotherapeutics.

1. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

2. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

3. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

4. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I

5. Identification, Localization in the Central Nervous System and Novel Myostimulatory Effect of Allatostatins in Tenebrio molitor Beetle